A 62-year-old woman with limited-stage small cell lung cancer (LD-SCLC) has completed 4 cycles of concurrent cisplatin–etoposide chemotherapy and thoracic radiotherapy (45 Gy in 30 fractions). Restaging CT chest shows complete response of the primary tumor and mediastinal nodes. Brain MRI is normal. She is asymptomatic. What is the most appropriate next step in management?

Explanation

## Prophylactic Cranial Irradiation (PCI) in Limited-Stage SCLC **Key Point:** Prophylactic cranial irradiation (PCI) is the standard of care for patients with limited-stage SCLC who achieve a complete or good partial response to initial chemoradiotherapy. It reduces the cumulative incidence of brain metastases from ~40% to ~15% and improves overall survival by ~5%. ### Evidence and Rationale **High-Yield:** The landmark trial (Aupérin et al., 1999) demonstrated that PCI in SCLC patients with complete response reduces brain relapse risk and improves 3-year overall survival (15% → 20.7%). This benefit is seen across both limited-stage and extensive-stage disease. **Clinical Pearl:** SCLC has a natural propensity for CNS sanctuary disease due to: - High growth fraction and early hematogenous dissemination - Chemotherapy and radiotherapy penetration into the brain is limited - Microscopic disease in the brain is present in ~25% of patients at diagnosis despite negative MRI ### Timing and Technique **Mnemonic:** **PCI = Post-Chemoradio Intervention** — delivered after completion of chemotherapy and thoracic radiotherapy, typically within 4–6 weeks of completing systemic treatment. - **Dose:** 25 Gy in 10 fractions (standard) or 30 Gy in 12 fractions - **Timing:** Within 4–6 weeks of completing chemotherapy (while disease control is optimal) - **Indication:** Complete or near-complete response to induction therapy - **Contraindication:** Extensive-stage disease with brain metastases (use therapeutic whole-brain RT instead) ### Comparison: PCI vs. Observation vs. Therapeutic WBRT | Scenario | Intervention | Rationale | |----------|--------------|----------| | LD-SCLC, complete response | PCI 25 Gy | Reduces brain relapse; improves OS | | LD-SCLC, no response | Observation or salvage therapy | PCI not indicated; poor prognosis | | ED-SCLC, brain mets present | Therapeutic WBRT 30 Gy | Treatment of established disease | | ED-SCLC, no brain mets, CR | PCI (controversial) | May be considered; less robust benefit than LD-SCLC | **Warning:** Common pitfalls: - Delaying PCI beyond 6 weeks reduces efficacy (increased risk of occult brain disease progression) - Confusing PCI (prophylactic, in responders) with therapeutic WBRT (in patients with brain metastases) - Omitting PCI in LD-SCLC responders—this significantly worsens prognosis ### Why Other Options Are Incorrect **Observation alone:** Without PCI, ~40% of LD-SCLC patients will develop brain metastases within 2 years, leading to poor quality of life and shortened survival. Observation is not standard of care after complete response. **Adjuvant topotecan:** There is no evidence for maintenance or adjuvant chemotherapy in SCLC after complete response to induction therapy. Topotecan is used for relapsed disease, not consolidation. **Therapeutic WBRT:** Reserved for patients with symptomatic or imaging-detected brain metastases, not for prophylaxis in asymptomatic patients. [cite:Harrison 21e Ch 111; NCCN Guidelines on Small Cell Lung Cancer]